<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107733">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02109263</url>
  </required_header>
  <id_info>
    <org_study_id>RB 12.143</org_study_id>
    <nct_id>NCT02109263</nct_id>
  </id_info>
  <brief_title>Prevention of the Procedural Pain in the Newborn</brief_title>
  <acronym>ACTISUCROSE</acronym>
  <official_title>Breastfeeding Versus Saccharose for Prevention of the Procedural Pain in the Newborn</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the impact of two non-medicinal strategies: the
      breast-feeding and saccharose to measure effects in cerebral cortex during pain using near
      infrared spectroscopy (NIRS)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies of non-medicinal treatments(saccharose and breast-feeding)show a decrease of
      expression of pain in newborn. However Slater and al questioned these practices due to the
      absence of modification of the cerebral answer measured by evoked potential.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Increase of the total concentration of haemoglobin</measure>
    <time_frame>Measure two minutes before painful gesture, at the moment of painful gesture and 2 minutes after painful gesture. The newborn will be followed for the duration of hospital stay, an expected average of 30 to 60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase of the total concentration of haemoglobin (delta HbT) measured by the spectrometer during the intravenous injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dosage of rate salivary cortisol</measure>
    <time_frame>before and after painful gesture</time_frame>
    <safety_issue>No</safety_issue>
    <description>Salivary cortisol sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Prevention of the Procedural Pain in the Newborn</condition>
  <arm_group>
    <arm_group_label>saccharose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20% saccharose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>breast-feeding</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>breast-feeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>saccharose versus breast-feeding</intervention_name>
    <description>saccharose versus breast-feeding</description>
    <arm_group_label>saccharose</arm_group_label>
    <arm_group_label>breast-feeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestationnel age included between 37 and 42 weeks

          -  Born in the CHRU of Brest

          -  Breast-Fed

          -  Score of Apgar upper to 7

          -  No pathology malformative

          -  Absence of known chromosomal abnormality

          -  Consent of parents

        Exclusion Criteria:

          -  Maternal drug use

          -  Morphinic treatment

          -  Barbiturate treatment

          -  Benzodiazépine treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>37 Weeks</minimum_age>
    <maximum_age>42 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Michel ROUE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pole de la femme, de la Mère et de l'Enfant, CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>July 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast-feeding</keyword>
  <keyword>Saccharose</keyword>
  <keyword>Breast-feeding newborn</keyword>
  <keyword>cortical pain responses</keyword>
  <keyword>near infrared spectroscopy (NIRS)</keyword>
  <keyword>Salivary rate cortisol</keyword>
  <keyword>heel lance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
